22774-64-7

Basic information

• Product Name: Benzenamine, 4-methyl-N-2-propynyl-
• Synonyms: 4-methyl-N-(prop-2-ynyl)benzenamine;N-(2-propynyl)-p-toluidine;3-(4-methylanilino)propyne;4-methyl-N-propargylaniline;4-methyl-N-(prop-2-ynyl)aniline;N-propargyl-N-p-tolylamine;Prop-2-ynyl-p-tolyl-amine
• CAS NO: 22774-64-7
• Molecular Formula: C10H11N
• Molecular Weight: 145.204
• Mol File: 22774-64-7.mol
• Article Data: 30

Chemical Properties

• Boiling Point: 99 - 100 °C (0.3 mmHg)
• CAS DataBase Reference: Benzenamine, 4-methyl-N-2-propynyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 4-methyl-N-2-propynyl-(22774-64-7)
• EPA Substance Registry System: Benzenamine, 4-methyl-N-2-propynyl-(22774-64-7)

Safety Data

• Hazardous Substances Data: 22774-64-7(Hazardous Substances Data)

Upstream product

• 106-49-0 p-toluidine 
• 106-96-7 propargyl bromide 
• 6165-75-9 propargyl benzenesulfonate 
• 6165-76-0 propargyl p-toluenesulfonate 
• 81634-47-1 N-<3-(trimethylsilyl)-2-propynylidene>-p-toluidine 
• 34646-08-7 3-Chlor-phenylsulfonsaeure-propargylester 
• 20569-03-3 propargyl m-nitrobenzenesulphonate 
• 34646-10-1 propargyl p-nitrobenzenesulphonate 
• 624-65-7 2-propynyl chloride 
• 659-86-9 propargyl iodide 
• 81634-54-0 N-<3-(trimethylsilyl)-2-propynyl>-p-toluidine 
• 16156-58-4 prop-2-yn-1-ol methanesulfonate 
• 1220042-37-4 C₁₃H₁₃NO₂ 
• 5720-05-8 4-methylphenylboronic acid 

Downstream Products

• 114382-10-4 1-[(4-methylphenyl)amino]propan-2-one 
• 100191-84-2 N-(prop-2-yn-1-yl)-N-(p-tolyl)acetamide 
• 126292-01-1 1-methyl-4-<3-(4-methylanilino)-1-propynyl>-4-piperidol 
• 123533-76-6 N-p-tolyl-N-(2-phenylsulphinylprop-2-enyl)amine 
• 88320-36-9 2,5-dihydro-1-(4-methylphenyl)-1H-pyrrole 
• 91-62-3 6-methylquinoline 
• 53498-57-0 4-chloro-5-methyl-3-oxo-3H-isoxazole-2-carboxylic acid 4-methyl-N-prop-2-ynyl-anilide 
• 1092371-37-3 9-[4-(p-tolylamino-methyl)-[1,2,3]triazol-1-yl]-5-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-5aH-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6-one 
• 1229444-82-9 C₁₉H₂₂F₃NO 
• 1229444-86-3 C₁₇H₁₉NO₃ 
• 1229444-81-8 C₁₈H₂₀F₃NO 
• 1229444-84-1 C₁₅H₁₄Cl₃NO 
• 1229444-78-3 C₁₅H₁₄F₃NO 
• 1229444-79-4 C₁₆H₁₆F₃NO 

Relevant articles and documents

Compound of dipyrrolopyridine structure Preparation method and medical application

The invention discloses a compound with a dipyrrolo-pyridine structure as well as a preparation method and medical application thereof. The compound provided by the invention has obvious inhibitory activity on JAK family proteins, is an effective JAK inhibitor, and has the prospect of being developed into drugs for inhibiting JAK and further treating diseases.

Synthesis and biological evaluation of coumarin-linked 4-anilinomethyl-1,2,3-triazoles as potent inhibitors of carbonic anhydrases ix and xiii involved in tumorigenesis

A series of coumarin-linked 4-anilinomethyl-1,2,3-triazoles (6a–t) was synthesized via a molecular hybridization approach, through carbon C-6 of the coumarin moiety. The synthesized compounds were evaluated for their inhibition of carbonic anhydrase (CA)

New ursolic acid derivatives bearing 1,2,3-triazole moieties: design, synthesis and anti-inflammatory activity in vitro and in vivo

Abstract: In order to discover novel anti-inflammatory agents, three series of compounds obtained by appending 1,2,3-triazole moieties on ursolic acid were designed and synthesized. All compounds have been screened for their anti-inflammatory activity by using an ear edema model. The potent anti-inflammatory compound was subjected to in vitro cyclooxygenase COX-1/COX-2 inhibition assays. In general, the derivatives were found to be potent anti-inflammatory activity. Especially, the compound 11b exhibited the strongest activity of all of the compounds prepared, with 82.81% inhibition after intraperitoneal administration, which was better than celecoxib as a positive control. Molecular docking results unclose the rationale for the interaction of the compound 11b with COX-2 enzyme. Further studies revealed that compound 11b exhibited effective COX-2 inhibitory activity, with half-maximal inhibitor concentration (IC50) value of 1.16?μM and selectivity index (SI = 64.66) value close to that of celecoxib (IC50 = 0.93?μM, SI = 65.47). Taken together, these results could suggest a promising chemotype for development of new COX-2-targeting anti-inflammatory agent. Graphic abstract: [Figure not available: see fulltext.]